Why Is Shattuck Labs (STTK) Stock Up 93% Today?

Shattuck Labs (NASDAQ:STTK) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients.…#shattucklabs #phase1a #acutemyeloidleukemia #aml #linipandite #sttk #palantirtechnologies #pltr #reshapelifesciences #williamwhite
Source: Reuters: Health - Category: Consumer Health News Source Type: news